Stifel Initiates Coverage On Neumora Therapeutics with Buy Rating, Announces Price Target of $26
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has initiated coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and a price target of $26.
October 10, 2023 | 9:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neumora Therapeutics has been initiated with a Buy rating by Stifel with a price target of $26.
The initiation of coverage by Stifel with a Buy rating and a price target of $26 indicates a positive outlook for Neumora Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100